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Abstract
Chronic gastroesophageal reflux disease is a known
risk factor for Barrett’s esophagus (BE), that induces
oxidative mucosal damage. Glutathione peroxidase-3
(GPx3) is a secretory protein with potent extracellular
antioxidant activity. Herein, we have investigated the
mRNA and protein expression of GPx3, and explored
promoter hypermethylation as an epigenetic mech-
anism for GPx3 gene inactivation during Barrett’s
carcinogenesis. Quantitative real-time reverse tran-
scription polymerase chain reaction on 42 Barrett’s ad-
enocarcinomas (BAs) revealed consistently reduced
levels of GPx3 mRNA in 91% of tumor samples. GPx3
promoter hypermethylation was detected in 62% of
Barrett’s metaplasia, 82% of dysplasia, and 88% of BA
samples. Hypermethylation of both alleles of GPx3 was
most frequently seen in BA (P = .001). Immunohisto-
chemical staining of GPx3 in matching tissue sections
(normal, BE, Barrett’s dysplasia, and BA) revealed a
weak-to-absent GPx3 staining in Barrett’s dysplasia
and adenocarcinoma samples where the promoter
was hypermethylated. The degree of loss of immuno-
histochemistry correlated with the hypermethylation
pattern (monoallelic versus biallelic). The observed
high frequency of promoter hypermethylation and
progressive loss of GPx3 expression in BA and its
associated lesions, together with its known function as
a potent antioxidant, suggest that epigenetic inactiva-
tion and regulation of glutathione pathway may be
critical in the development and progression of BE.
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Introduction
Gastroesophageal reflux disease (GERD) is a major public
health problem, with a prevalence of 5% to 7% in the gen-
eral population [1,2]. Approximately 10% of patients with
chronic GERD develop a metaplastic condition, where the
normal squamous epithelium of the distal esophagus is often re-
placed by a columnar or intestinalized epithelium with goblet
cells, known as Barrett’s esophagus (BE). In the setting of con-
tinued injury asa result ofGERD,BE is a premalignant lesion that
can ultimately progress from metaplasia to dysplasia, and sub-
sequent Barrett’s adenocarcinoma (BA) [3–6]. BA has one of
the fastest-growing incidence rates in the Western world [7–9].
Reactive oxygen species (ROS) play a significant role in the
pathogenesis of several diseases of the gastrointestinal (GI)
tract, including GERD, BE, and gastritis [10,11]. ROS are po-
tential carcinogens that facilitatemutagenesis, tumor promotion,
and progression. Although the extent of the contribution made
by oxidative DNA damage has not been well defined, it appears
that ROS-induced DNA damage cannot only initiate carcinogen-
esis, but also facilitate tumor progression [12–15].
Cells have an antioxidant system that controls the balance
between production and removal of oxygen radicals, thereby
protecting against oxidative damage. Antioxidant defensive
mechanisms include the enzymes superoxide dismutase, cata-
lase, and glutathione peroxidase (GPx), as well as non-
enzymatic compounds such as a-tocopherol, b-carotene,
vitamin C, and glutathione [16,17]. In the GI tract, several
peroxide-reducing enzymes are found, including members of
the GPx and peroxiredoxin families.
GPx catalyzes the conversion of hydrogen peroxide
and lipid peroxides at the expense of glutathione, and is a
major scavenger of ROS produced during normal metabolism
or after oxidative insult [18]. GPx2 is found in the GI tract and
plays a role in colon cancer resistance, whereas plasma
glutathione peroxidase-3 (GPx3) is identified in the normal
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tissues of the esophagus, stomach, small bowel, and colon
[19]. GPx3 is an extracellular glycosylated enzyme that
can use glutathione, thioredoxin, and glutaredoxin as elec-
tron donors, to reduce a broad range of hydroperoxides
[20,21]. It reduces hydroperoxides, including fatty acid hydro-
peroxides and phospholipid hydroperoxides [22,23]. In-
creased production of mucosal ROS has been demonstrated
to occur in BE, suggesting a role for cellular injury in carcino-
genesis [24–28]. Antioxidant defenses are therefore criti-
cal in the protection of the epithelium against DNA damage
and mutation.
The abnormal hypermethylation of CpG sites associated
with tumor-suppressor genes can cause transcriptional si-
lencing and is recognized as an important mechanism for
gene inactivation in cancer cells [29,30]. Evidence support-
ing this mechanism of gene inactivation has been observed
in BE and many types of human cancer, including esopha-
geal adenocarcinoma [31–33].
To elucidate the role of GPx3 in Barrett’s tumorigenesis,
we have investigated the mRNA expression level, promoter
methylation status, and protein expression of GPx3 in Bar-
rett’s metaplasia, dysplasia, and adenocarcinoma.
Materials and Methods
Tissue Samples
Forty-two frozen tissue samples of Barrett’s-related, gas-
troesophageal junction (GEJ) and lower esophageal adeno-
carcinomas were collected for the analysis of GPx3 mRNA
expression by quantitative real-time reverse transcription
polymerase chain reaction (RT-PCR). In addition, 19 normal
esophageal and gastric mucosa samples were used as
controls for comparison of GPx3 mRNA expression. From
the 42 samples with BA, DNA from 12 samples were avail-
able for simultaneous analysis for GPx3 promoter methyla-
tion. An additional 22 BA tissue samples were processed
for DNA extraction to give a total of 34 BA DNA samples. In
addition, DNA was purified from 21 BE, 11 BE with dysplasia,
and 12 normal esophageal mucosa samples. All DNA sam-
ples were analyzed by methylation-specific PCR (MSP). In
addition, 55 BA tissues with adjacent BE, dysplasia, and
normal tissues were formalin-fixed and embedded in paraffin
for immunohistochemical analysis. The histopathology was
verified in all tissues (A.R., M.V., and C.A.M.). All clinical tis-
sue samples and histopathologic information were obtained
according to approved institutional guidelines at the Univer-
sity of Virginia (Charlottesville, VA) and Otto-von-Guericke
University (Magdeburg, Germany). The adenocarcinomas
collected ranged from well-differentiated (WD) to poorly
differentiated (PD), stages I to IV, with a mix of intestinal-
type and diffuse-type tumors.
Quantitative Real-Time RT-PCR
mRNA was isolated using the RNeasy kit (Qiagen, Gmbh,
Hilden, Germany), then single-stranded cDNA was subse-
quently synthesized using the Advantage RT-for-PCR Kit
(Clontech, Palo Alto, CA). Quantitative real-time RT-PCR
Figure 1. Loss of GPx3 expression in BAs. Quantitative real-time RT-PCR was performed on 42 BAs using iCycler (BioRad), in a comparison with 19 normal
esophageal and gastric mucosa samples. The horizontal axis shows sample numbers, whereas the fold expression in tumor samples compared to normal is shown
in the vertical axis. The expression fold was calculated according to the formula: 2(Rt  Et)/2(Rn  En), as described elsewhere [34]. Each bar represents one tumor
sample. Downregulation is shown as negative expression fold values. The displayed mean expression fold for each tumor sample is calculated in comparison with
expression in 19 normal samples. The standard error of the mean is shown (±SEM). The expression of GPx3 was normalized to the expression of HPRT1, which
showed minimal variation in all normal and neoplastic samples tested. The loss of GPx3 mRNA expression was universal and did not statistically correlate with any
of the histopathologic parameters investigated.
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was performed in 42 BA samples and 19 normal gastric
mucosal samples, using an iCycler (Bio-Rad, Hercules, CA);
threshold cycle number was determined using the iCycler
software (version 3.0; BioRad, Hercules, CA), as described
earlier [34]. The primers used for real-time RT-PCR were
obtained from GeneLink (Hawthorne, NY), and their se-
quences are available on request. Reactions were per-
formed in triplicate, and threshold cycle numbers were
averaged. A single melt curve peak was observed for each
sample used in data analysis, thus confirming the purity and
specificity of all amplified products. The results for GPx3
were normalized to HPRT1, which had minimal variation in
all normal and neoplastic gastric samples tested. The fold
expression in tumors was calculated, compared to normal
samples, and normalized with HPRT1 values according to
the formula: 2(Rt  Et)/2(Rn  En), as described elsewhere [34].
Rt is the threshold cycle number for the reference gene
observed in the tumor, Et is the threshold cycle number for
the experimental gene observed in the tumor, Rn is the
threshold cycle number for the reference gene observed
in the normal sample, and En is the threshold cycle number
for the experimental gene observed in the normal sample. Rn
and En values were taken from the 19 normal mucosa
samples that were analyzed. Each tumor sample was com-
pared to the 19 normal samples, and the relative fold
expression in tumors, with standard error of the mean
(±SEM), is shown in Figure 1.
MSP
DNA was prepared from three to seven 10-mm sections
taken from representative paraffin blocks using the Nucleo-
Spin Tissue Kit (Machery and Nagel, Duren, Germany). On a
mirror-imaged H&E slice, the region of interest was marked,
and tissues were manually scraped off to ensure a specific
cell population of more than 80% in the preparation. Geno-
mic DNA were extracted from the cell lines by a standard
phenol–chloroform procedure. Extracted DNA was bisulfite-
modified using the CpGenome DNA modification kit (Inter-
gen, Purchase, NY), as described previously [35]. Briefly,
all unmethylated cytosines were deaminated and converted
to uracils, whereas 5-methylcytosines remained unaltered.
Modified DNA was used as a template for MSP, which was
carried out using primers specific for either methylated or
modified–unmethylated sequences. CpGenome universal
methylated DNA (Intergen) was used as a positive control,
whereas DNA from normal lymphocytes was used as a
negative control for methylated alleles.
Primers were designed for the CpG-rich region around
the start of exon 1 (positions 1984–2201; http://egp.gs.
washington.edu), which consists of 17 CpG dinucleo-
tides. The modified DNA was subjected to MSP using the
following GPx3-specific primers: for methylated sequences,
sense 5V-GGTGGGGAGTTGAGGGTAAGTC-3V and anti-
sense 5V-CCTACAACAACCGAACCATAACGAAA-3V; and
for unmethylated sequences, sense 5V-GGTGGGGAGTT-
GAGGGTAAGTT-3V and antisense 5V-CCTACAACAACCA-
AACCATAACAAAA-3V (CpGs are given in bold letters). Both
these pairs generate PCR products of 219 bp. Methylated
PCR products of 12 samples were directly sequenced (se-
quencing primer: 5V-GGTGGGGAGTTGAGGGTA-3V, which
can bind to both methylated and unmethylated sequences)
using rhodamine dye terminator chemistry (Big DyeTer-
minator v1.1 Cycle Sequencing Kit; Applied Biosystems,
Foster City, CA) and POP-6 polymer on an ABI PRISM 310
capillary sequencer.
For PCR, 2 ml of bisulfite-modified DNA was amplified in
a total volume of 25 ml, containing 1 PCR buffer, 3 mM
MgCl2, 12.5 pmol of each primer, 160 mM dNTPs, and 0.5 U
of Hot-Goldstar Taq polymerase (Eurogentec, San Diego,
CA). PCR conditions were 95jC for 10 minutes, 35 cycles of
95jC for 1 minute, annealing at 60jC (unmethylated) or
64jC (methylated) for 1 minute and 72jC for 1 minute,
Figure 2. GPx3 promoter methylation status. BE, Barrett’s esophagus; BA,
Barrett’s adenocarcinoma. Black boxes indicate biallelic methylation (M+/M+)
and gray boxes indicate monoallelic methylation (M+/M) as detected in
MSP, whereas blank boxes indicate samples that are only unmethylated
(M/M). GPx3 promoter hypermethylation was detected in 30 of 34 (88.2%)
adenocarcinoma samples, with 16 samples showing biallelic methylation. Of
the dysplasia samples, 9 of 11 (81.8%) were methylated, with only one
sample showing biallelic methylation. In Barrett’s metaplasia, methylation
was only detectable in 13 of 21 samples (61.9%). Ten of 12 normal samples
were unmethylated, with only monoallelic methylation in the remaining two
normal samples. Among 12 samples available for the comparison of mRNA
expression level and methylation status, nine samples had downregulation of
GPx3 mRNA levels together with hypermethylation.
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followed by a final extension step at 72jC for 10 minutes.
PCR products were electrophoresed on polyacrylamide gels
and visualized by silver staining.
5-Aza-Cytidine Treatment in Cell Lines
MKN45 cells were cultured in RPMI 1640 supplemented
with 10% FCS. The MKN45 cells that did not express GPx3
mRNA and for which homozygously (biallelic) methylated
promoter status had been confirmed were treated with
5-aza-cytidine (Sigma, St. Louis, MO) that had been dis-
solved in cold RPMI 1640 immediately prior to use. Cells
were grown in a medium containing 1 mM 5-aza-cytidine for
4 days, with the medium and drug being replaced every
48 hours. After 4 days, the drug was removed and the
cells were allowed to recover for a further 48 hours (total
of 144 hours).
Immunohistochemistry (IHC)
Immunohistochemical analysis of GPx3 protein expres-
sion was performed on 55 formalin-fixed, paraffin-embedded
tissue samples that included BE, dysplasia, BA, and normal
esophageal tissue sections, to determine concordance with
results from MSP. Dewaxing and rehydration by descend-
ing concentrations of ethanol were followed by antigen re-
trieval (20 minutes in a microwave, 450 W, 10 mM EDTA,
pH 8.0). Blocking was done with 10% goat serum in PBS
for 5 minutes. All sections were incubated with antihuman
GPx (monoclonal mouse IgG1n, GPx-347, dilution 1:20, MBL;
MoBiTec, Go¨ttingen, Germany) for 1 hour at room tempera-
ture, then washed in PBS. For revealing positive immuno-
histochemical reaction, the Vectastain ABC-AP kit (mouse
IgG, vector; Alexis, Gruenberg, Germany) was used as chro-
mogen substrate, and the specimens were counterstained
with hematoxylin and mounted with DEPEX. Specificity of
immunostaining was checked by omitting single steps in
the protocol, and by replacing the primary antibody with
nonimmune serum. Slides were examined by two indepen-
dent reviewers blinded to their identity.
Results
Reduced Levels of GPx3 mRNA Were Found in BAs
Compared with Normal Mucosa
We detected comparably high mRNA expression levels
of GPx3 mRNA in all 19 normal mucosae. A quantitative
real-time RT-PCR analysis of 42 Barrett’s-related adenocar-
cinomas included all stages of development (TNM stages
I–IV), histopathology (WD to PD, intestinal type and diffuse
type), and location (lower esophageal to GEJ). This analysis
revealed consistently low levels of GPx3 expression in 90.5%
(38 of 42) of BA samples compared with 19 normal mucosal
samples. There was a dramatic reduction in levels of GPx3
in more than half of the cases, with a 10-fold reduction com-
pared with the normal samples (Figure 1). The loss of GPx3
was universal and did not statistically correlate with any of
the histopathologic parameters investigated.
High Frequency of GPx3 Promoter Methylation
Observed in BAs
MSP revealed frequent monoallelic (one band for methyl-
ated product and one band for unmethylated product) and
biallelic (one band for methylated product) GPx3 pro-
moter methylation in tumor samples and preneoplastic dys-
plasia. However, only 2 of 12 normal esophageal mucosa
samples that were studied with MSP showed GPx3 pro-
moter hypermethylation, which was always monoallelic
(Figures 2–4). Furthermore, these two samples were taken
from patients with adjacent BE, one of whom had biallelic
GPx3 promoter hypermethylation and the other monoallelic
GPx3 promoter hypermethylation (Figure 2, B11 and B12).
Thus, methylation in normal samples may be due to a con-
taminant cell population that was not identified histologically.
However, GPx3 promoter hypermethylation was detected in
61.9% (13 of 21) of Barrett’s metaplasia, 81.8% (9 of 11) of
dysplasia, and 88.2% (30 of 34) of BA samples (Table 1 and
Figure 2). Among the samples with GPx3 promoter hyper-
methylation, 6 BE, 1 dysplastic, and 16 BA samples showed
Figure 3. MSP analysis of the GPx3 promoter region. (A) This figure shows two cases of matched normal mucosa and BA (B4 and B5), one case of matched BE
and BA (B22), and one sample of matched dysplasia and BA (B29). Unmethylated (un) and methylated (m) PCR products are shown. (B) MSP of the GPx3
promoter after the treatment of MKN45 cells with 5-aza-cytidine for 24, 48, and 96 hours. A slight unmethylated band can be recognized already after 96 hours of
treatment with 5-aza-cytidine. After an additional 48 hours of recovery from the drug (96R), the unmethylated band further increases and the methylated and
unmethylated PCR bands reach similar signal intensities.
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biallelic hypermethylation. These data clearly demonstrate a
significant correlation between histomorphologic diagnosis
and GPx3 promoter hypermethylation (P = .001).
Treatment with 5-Aza Demethylates GPx3 Promoter
and Restores mRNA Expression in MKN45 Cells
The MSP following 5-aza-cytidine treatment of the MKN
cell line revealed an intense unmethylated band, whereas
the methylated band nearly disappeared. RT-PCR demon-
strated a significant increase in the level of GPx3 mRNA
expression after 96 hours of treatment followed by 48 hours
of recovery from the drug (Figure 3). Thus, these results con-
firmed that promoter methylation plays an essential role in
the silencing of GPx3 expression.
GPx3 Promoter Methylation Correlates with Loss of
GPx3 mRNA and Protein Expression
Of the 34 BA samples that were subjected to methylation
analysis, 12 samples were further analyzed using quantita-
tive real-time RT-PCR to measure GPx3 mRNA expression.
All but two revealed low GPx3 expression and nine of them
corresponded to promoter hypermethylation (Figure 2). One
sample had no detectable GPx3 promoter methylation and
showed a minimal reduction of gene expression (B44).
Figure 3 demonstrates a representative gel electrophoresis
image for MSP of matched normal mucosa and BA, BE, or
dysplasia. Bisulfite sequencing of 12 methylated samples
identified the CpG sites, within the GPx3 promoter region
that we studied, that were vulnerable to methylation
(Figure 4). Immunohistochemical analysis of GPx3 protein
expression was performed on all samples that were sub-
jected to methylation analysis in this study. High expression
levels, determined by a strong, diffuse staining of the cyto-
plasm, was found in all normal esophageal and Barrett’s
epithelia tissues that had unmethylated promoter regions. In
contrast, BA and nearby dysplasia, which were determined
to be methylated, had weak to absent immunostaining for
GPx3 protein (Figure 5).
Discussion
In this study, we have demonstrated that loss of the GPx3
mRNA and protein expression is a consistent and progres-
sive molecular alteration during Barrett’s tumorigenesis that
occurs due to hypermethylation of the GPx3 promoter. A
monoallelic methylation pattern associated with partial loss
of GPx3 expression was seen as early as metaplasia.
However, a more frequent and consistent biallelic methyla-
tion, together with a dramatic loss of GPx3 expression, was
demonstrated in almost all BA samples. This observation in-
dicates that methylation of one allele starts as early as meta-
plasia, whereas for cancer samples, both alleles become
methylated, with a dramatic loss of expression of GPx3. This
finding is particularly interesting because Barrett’s tumors
arise following a characteristic sequence of events that
is initiated by chronic GERD. Several reports have demon-
strated increased mucosal ROS levels in reflux esophagitis
and BE [24–27]. ROS are mainly produced by phagocytic
cells, neutrophils, and epithelial cells as a consequence
of inflammatory tissue damage [36], and have been impli-
cated as important factors for both tissue and DNA damage
[13–15]. Additionally, it has previously been demonstrated
Figure 4. Sequencing analysis of the GPx3 promoter region. Twelve samples showing a methylated band were randomly chosen for bisulfite sequencing. The
figure shows the methylation pattern of a partial GPx3 promoter region that was used for MSP analysis, consisting of 14 CpG sites. Three additional CpG sites were
already covered by the primer regions. Gray circles indicate the presence of a C and a T at the same position, reflecting a partial methylation, whereas closed
circles indicate methylated sites (only a C was seen). These data demonstrate a dense methylation of CpG sites in this GPx3 promoter region.
Table 1. Frequency of GPx3 Promoter Hypermethylation According to
Histomorphologic Diagnosis.
GPx3 Methylation Status Histologic Diagnosis
Normal
(n = 10)
BE
(n = 21)
Dysplasia
(n = 11)
BA
(n = 34)
No methylation (M) 10 (83%) 8 (38%) 2 (18%) 4 (12%)
Monoallelic (M+/M) 2 (17%) 7 (33%) 8 (73%) 14 (41%)
Biallelic (M+/M+) 0 6 (29%) 1 (9%) 16 (47%)*
M, methylation; () negative; (+) positive. Monallelic methylated samples
displayed one band for methylated product (M+) and one band for un-
methylated product (M). In biallelic methylation, only one band that repre-
sents the MSP product was visualized (M+/M+).
*Biallelic methylation was significantly more frequent in BA ( P < .01).
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Figure 5. Immunohistochemical analysis for human GPx. Immunohistochemical staining was performed using the GPx-347 monoclonal mouse IgG1j antibody. (A)
Normal esophageal squamous epithelium and columnar Barrett’s epithelium, determined as unmethylated by MSP, show strong, diffuse cytoplasmic staining (red
color) representing a normal expression of GPx (original magnification, 200) (indicated by arrows). (B) Barrett’s epithelium with monoallelic methylation of GPx
shows weak protein expression (indicated by *) and demonstrates loss of GPx immunoreactivity in dysplastic epithelia (indicated by **) with determined biallelic
methylation (original magnification, 100). (C) Barrett’s epithelium, determined as unmethylated, shows moderate to strong, diffuse cytoplasmic staining (original
magnification, 400) (indicated by arrows). (D) Barrett’s epithelium with biallelic methylation shows complete loss of immunoreactivity (original magnification,
200) (indicated by **). (E and F) In BA lacking methylation of the GPx promoter, a strong, diffuse cytoplasmic staining was observed (original magnification, 100
and 200) (indicated by arrows). (G and H) BA with biallelic methylation demonstrates loss of immunoreactivity for a GPx antibody (original magnification, 100
and 400) (indicated by **).
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that the levels of glutathione are markedly decreased in
Barrett’s epithelium [37], suggesting that the antioxidant
defense mechanism is impaired in this premalignant lesion.
GPx is considered to be the first line of defense for the pro-
tection of epithelial cells against this oxidative damage
process. GPx3 is a secreted isoform of GPx and is an ef-
ficient extracellular antioxidant [38,39].
Mo¨rk et al. [19] demonstrated that both plasma GPx3
and GI GPx1 and GPx2 are expressed in the normal mucosa
of the esophagus. GPx3 mRNA expression was markedly
high in the squamous epithelium of the esophagus, which
may represent a characteristic and physiological feature of
squamous esophageal mucosa. In particular, the high ex-
pression levels may contribute to adequate extracellular
neutralization of ROS [19]. We observed a constantly low
level of expression of GPx3 mRNA in mucosal samples
from BE and BA, with the adenocarcinomas showing a par-
ticularly dramatic loss of GPx3 expression. This finding was
confirmed immunohistochemically, where a remarkable loss
of GPx3 immunostaining in all studied Barrett’s dysplasia
and adenocarcinoma samples was contrasted by a strong,
diffuse cytoplasmic staining in the normal esophageal mu-
cosa samples. These findings suggest that GPx3 func-
tion is impaired in BE, a consequence of which is likely to
be an increased amount of hydrogen peroxide and other
ROS. This would induce DNA damage, driving the carcino-
genic process to the final stages of BA.
In this study, we investigated GPx3 promoter hyper-
methylation as a mechanism of GPx3 gene silencing. We
have demonstrated a significant correlation of GPx3 pro-
moter hypermethylation and the appearance of BE and
adenocarcinoma. In addition, significant GPx3 promoter
hypermethylation was detected in the majority of BE, dys-
plasia, and BAs, but not in normal esophageal mucosa.
Moreover, there was a strong concordance between the
promoter hypermethylation of GPx3 and the data obtained
during mRNA and immunohistochemical analyses. Promoter
hypermethylation resulted in the downregulation of mRNA
levels in 9 of 11 samples and reduced or loss of protein
expression in samples with monoallelic or biallelic methy-
lation, respectively. These data provide strong evidence
that GPx3 promoter hypermethylation is a main mechanism
involved in GPx3 gene inactivation, resulting in impaired
GPx3 function. This impairment could be an important step
in the neoplastic transformation of BE.
In addition to the hypermethylation seen in pathologic
lesions, we detected monoallelic GPx3 promoter hyper-
methylation in 2 of 12 normal esophageal mucosal samples.
Interestingly, these two samples were adjacent to BE and/or
dysplasia that had GPx3 promoter hypermethylation, sug-
gesting that GPx3 promoter hypermethylation may be an
early epigenetic event during the multistep process of neo-
plastic progression in BE. If this were the case, then these
samples may represent submicroscopic lesions that were
beyond histologic evaluation, but were susceptible to the
development of BE. Similar observations were made for
the tumor-suppressor gene CDKN2/p16, with respect to pro-
moter hypermethylation in BE [33].
In summary, we have demonstrated constantly lowmRNA
and protein expression levels of GPx3 in BAs. Promoter
hypermethylation of GPx3 started as early as BE and was
often seen as monoallelic. However, GPx3 biallelic hyper-
methylation and inactivation increased significantly with
progression toward neoplasia. Therefore, epigenetic inacti-
vation of GPx3 may play an important role in the develop-
ment of BE and its carcinogenesis cascade.
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